person · Reporting owner

GOWEN MAXINE

Disclosed activity across 6 companies

Tapewire entity: 40436
SEC CIK: 0001280044

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aceragen, Inc.ACGN · Entity 110652	Director	August 10, 2023	August 11, 2023
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 04, 2026	June 08, 2026
Akebia Therapeutics, Inc.AKBA · Entity 6105	Director	June 05, 2020	June 09, 2020
Merus N.V.MRUS · Entity 70740	Director	December 12, 2025	December 12, 2025
Passage BIO, Inc.PASG · Entity 7829	Director	May 19, 2026	May 21, 2026
TREVENA INCTRVN · Entity 85383	Director	May 13, 2020	May 15, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aceragen, Inc.

Report date August 10, 2023 · Filed August 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Trust	0	Reported balance After 2023-08-10 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-08-10 · Sale · Disposed 51 · Balance 0 F1: Shares of common stock held in the name Brian Macdonald for Maxine Gowen Trust, for which the Reporting Person is a beneficiary and trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock held in the name Brian Macdonald for Maxine Gowen Trust, for which the Reporting Person is a beneficiary and trustee.

Aclaris Therapeutics, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,334	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 33,334 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03	Direct	42,350	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	10,987	Reported balance After 2026-06-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

F5: The shares underlying these restricted stock units vested on June 5, 2026.

Akebia Therapeutics, Inc.

Report date June 05, 2020 · Filed June 09, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,133	Ending reported balance After 2020-06-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-06-05 · Grant · Acquired 13,700 · Balance 28,700 F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Row 2 · 2020-06-08 · Sale · Disposed 4,567 · Balance 24,133 F2: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.96 · Expires 2030-06-05	Direct	20,100	Reported balance After 2020-06-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-06-05 · Grant · Acquired 20,100 · Balance 20,100 F3: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

F2: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019.

F3: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

Merus N.V.

Report date December 12, 2025 · Filed December 12, 2025

Security / award	Ownership account	Disclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.60 · Expires 2035-05-22	Direct	Reported balance After 2025-12-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-12-12 · Disposition to issuer · Disposed 13,193 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.73 · Expires 2034-05-07	Direct	Reported balance After 2025-12-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-12 · Disposition to issuer · Disposed 8,844 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2033-06-08	Direct	Reported balance After 2025-12-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-12 · Disposition to issuer · Disposed 14,414 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2032-05-31	Direct	Reported balance After 2025-12-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-12 · Disposition to issuer · Disposed 16,604 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-05-28	Direct	Reported balance After 2025-12-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-12 · Disposition to issuer · Disposed 12,240 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.06 · Expires 2030-10-23	Direct	Reported balance After 2025-12-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-12 · Disposition to issuer · Disposed 7,957 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Filing footnotes · ownership attribution and instrument terms

F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Passage BIO, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19	Direct	10,539	Reported balance After 2026-05-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

TREVENA INC

Report date May 13, 2020 · Filed May 15, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2030-05-13	Direct	64,103	Reported balance After 2020-05-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-05-13 · Grant · Acquired 64,103 · Balance 64,103 F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001280044-26-000004 · form4-06082026_040601.xml · derivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 5, 2026. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	11,580	Not disclosed	Not disclosed	Disclosure SEC source: 0001280044-26-000004 · form4-06082026_040601.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	10,987	$0.00	$0.00	Disclosure SEC source: 0001280044-26-000004 · form4-06082026_040601.xml · derivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Underlying: Common Stock · 10,987 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $4.71	$0.00	Disclosure SEC source: 0001280044-26-000004 · form4-06082026_040601.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
May 19, 2026 Filed May 21, 2026 20:11 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (right to buy) · Derivative	10,539	$0.00 Strike: $5.08	$0.00	Disclosure SEC source: 0001280044-26-000002 · form4-05212026_080523.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,539 Underlying: Common Stock · 10,539 shares Expires 2036-05-19 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
December 12, 2025 Filed Dec 12, 2025 23:49 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	7,957	$0.00 Strike: $13.06	$0.00	Disclosure SEC source: 0001193125-25-317924 · ownership.xml · derivative · entry 6 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 7,957 shares Expires 2030-10-23 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 23:49 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	12,240	$0.00 Strike: $21.15	$0.00	Disclosure SEC source: 0001193125-25-317924 · ownership.xml · derivative · entry 5 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,240 shares Expires 2031-05-28 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 23:49 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	16,604	$0.00 Strike: $18.56	$0.00	Disclosure SEC source: 0001193125-25-317924 · ownership.xml · derivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 16,604 shares Expires 2032-05-31 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 23:49 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	14,414	$0.00 Strike: $23.29	$0.00	Disclosure SEC source: 0001193125-25-317924 · ownership.xml · derivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 14,414 shares Expires 2033-06-08 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 23:49 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	8,844	$0.00 Strike: $48.73	$0.00	Disclosure SEC source: 0001193125-25-317924 · ownership.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,844 shares Expires 2034-05-07 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 23:49 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	13,193	$0.00 Strike: $41.60	$0.00	Disclosure SEC source: 0001193125-25-317924 · ownership.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,193 shares Expires 2035-05-22 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016248 · form4-06092025_040604.xml · derivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2025. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2025. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,793	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-016248 · form4-06092025_040604.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016248 · form4-06092025_040604.xml · derivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580 Underlying: Common Stock · 11,580 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0001415889-25-016248 · form4-06092025_040604.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
May 28, 2025 Filed May 30, 2025 23:31 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (right to buy) · Derivative	201,857	$0.00 Strike: $0.36	$0.00	Disclosure SEC source: 0001415889-25-015059 · form4-05302025_110508.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,857 Underlying: Common Stock · 201,857 shares Expires 2035-05-28 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
May 22, 2025 Filed May 27, 2025 12:00 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	13,193	$0.00 Strike: $41.60	$0.00	Disclosure SEC source: 0000950170-25-077382 · ownership.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,193 Underlying: Common Shares · 13,193 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options vest over a one-year period commencing on May 22, 2025 in 12 equal monthly installments. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-24-016195 · form4-06102024_040609.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,793 Underlying: Common Stock · 4,793 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001415889-24-016195 · form4-06102024_040609.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 01, 2024 Filed Jun 4, 2024 20:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015363 · form4-06042024_040608.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document
June 01, 2024 Filed Jun 4, 2024 20:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,660	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015363 · form4-06042024_040608.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
May 21, 2024 Filed May 23, 2024 20:56 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (right to buy) · Derivative	47,693	$0.00 Strike: $1.28	$0.00	Disclosure SEC source: 0001415889-24-014313 · form4-05232024_080547.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,693 Underlying: Common Stock · 47,693 shares Expires 2034-05-21 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
May 07, 2024 Filed May 9, 2024 20:30 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	8,844	$0.00 Strike: $48.73	$0.00	Disclosure SEC source: 0000950170-24-057081 · ownership.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,844 Underlying: Common Shares · 8,844 shares Expires 2034-05-07 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 7, 2024 in 12 equal monthly installments. Read SEC document
August 10, 2023 Filed Aug 11, 2023 16:48 UTC	Aceragen, Inc. ACGN · Entity 110652	SaleCommon Stock	51	$0.51	$26.01	Disclosure SEC source: 0001415889-23-012145 · form4-08112023_080800.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · ownership.nature: Shares of common stock held in the name Brian Macdonald for Maxine Gowen Trust, for which the Reporting Person is a beneficiary and trustee. Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:15 UTC	Merus N.V. MRUS · Entity 70740	GrantShare option (right to buy) · Derivative	14,414	$0.00 Strike: $23.29	$0.00	Disclosure SEC source: 0001209191-23-036267 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,414 Underlying: Common Shares · 14,414 shares Expires 2033-06-08 F1 · derivative.exercise_date: Options vest over a one-year period commencing June 8, 2023 in 12 equal monthly installments. Read SEC document
June 02, 2023 Filed Jun 5, 2023 21:04 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034459 · doc4.xml · derivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document
June 02, 2023 Filed Jun 5, 2023 21:04 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,507	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034459 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:04 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034459 · doc4.xml · derivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:04 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $8.70	$0.00	Disclosure SEC source: 0001209191-23-034459 · doc4.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document
May 25, 2023 Filed May 26, 2023 20:24 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0001209191-23-032545 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
June 23, 2022 Filed Jun 27, 2022 16:31 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantStock Option (Right to Buy) · Derivative	26,000	$0.00 Strike: $0.46	$0.00	Disclosure SEC source: 0001415889-22-006943 · form4-06272022_040647.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-23 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document
June 03, 2022 Filed Jun 6, 2022 21:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034582 · doc4.xml · derivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document
June 03, 2022 Filed Jun 6, 2022 21:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	3,356	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-034582 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 02, 2022 Filed Jun 6, 2022 21:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034582 · doc4.xml · derivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document
June 02, 2022 Filed Jun 6, 2022 21:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $14.48	$0.00	Disclosure SEC source: 0001209191-22-034582 · doc4.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document
May 31, 2022 Filed Jun 1, 2022 20:27 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $1.80	$0.00	Disclosure SEC source: 0001209191-22-033163 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-05-30 F1 · derivative.exercise_date: The stock option vests in ratable increments of 1/12 of the total award on each monthly anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
May 31, 2022 Filed Jun 2, 2022 20:06 UTC	Merus N.V. MRUS · Entity 70740	GrantShare option (right to buy) · Derivative	16,604	$0.00 Strike: $18.56	$0.00	Disclosure SEC source: 0000899243-22-020675 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,604 Underlying: Common Shares · 16,604 shares Expires 2032-05-31 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 31, 2022 in 12 equal monthly installments. Read SEC document
May 26, 2022 Filed May 31, 2022 20:22 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $1.76	$0.00	Disclosure SEC source: 0001209191-22-032812 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
June 08, 2021 Filed Jun 10, 2021 17:25 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantStock Option (Right to Buy) · Derivative	26,000	$0.00 Strike: $1.31	$0.00	Disclosure SEC source: 0001415889-21-002922 · form4-06102021_050601.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-08 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2021 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 8, 2022 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document
June 03, 2021 Filed Jun 4, 2021 23:55 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038444 · doc4.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document
June 03, 2021 Filed Jun 4, 2021 23:55 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	12,250	$0.00 Strike: $21.90	$0.00	Disclosure SEC source: 0001209191-21-038444 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document
May 28, 2021 Filed Jun 2, 2021 20:10 UTC	Merus N.V. MRUS · Entity 70740	GrantShare option (right to buy) · Derivative	12,240	$0.00 Strike: $21.15	$0.00	Disclosure SEC source: 0000899243-21-021549 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,240 Underlying: Common Shares · 12,240 shares Expires 2031-05-28 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 28, 2021 in 12 equal monthly installments. Read SEC document
May 28, 2021 Filed Jun 16, 2021 20:05 UTC Amendment	Merus N.V. MRUS · Entity 70740	GrantShare option (right to buy) · Derivative	12,240	$0.00 Strike: $21.15	$0.00	Disclosure SEC source: 0000899243-21-024126 · doc4a.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,240 Underlying: Common Shares · 12,240 shares Expires 2031-05-28 F1 · derivative.exercise_date: Options vest as to 33% on May 28, 2022 and as to 1/24th monthly thereafter, subject to the non-executive director continuing in service as a non-executive director through each such vesting date. Read SEC document
May 27, 2021 Filed Jun 1, 2021 17:51 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (Right to Buy) · Derivative	4,542	$0.00 Strike: $13.83	$0.00	Disclosure SEC source: 0001209191-21-036754 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,542 Underlying: Common Stock · 4,542 shares Expires 2031-05-26 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 18, 2021 Filed Feb 22, 2021 22:45 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantStock Option (right to buy) · Derivative	33,836	$0.00 Strike: $21.46	$0.00	Disclosure SEC source: 0001209191-21-012828 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,836 Underlying: Common Stock · 33,836 shares Expires 2031-02-17 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on March 18, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 08, 2020 Filed Jun 9, 2020 20:17 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	SaleCommon Stock	4,567	$12.05	$55,032.35	Disclosure SEC source: 0001562180-20-004358 · primarydocument.xml · nonDerivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,133 F2 · kind: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019. Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:17 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	GrantStock Option (Right to buy) · Derivative	20,100	$0.00 Strike: $11.96	$0.00	Disclosure SEC source: 0001562180-20-004358 · primarydocument.xml · derivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2030-06-05 F3 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:17 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	GrantCommon Stock	13,700	$0.00	$0.00	Disclosure SEC source: 0001562180-20-004358 · primarydocument.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document
June 04, 2020 Filed Jun 8, 2020 21:45 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantOption Grant (right to buy) · Derivative	16,500	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001209191-20-035056 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document
May 13, 2020 Filed May 15, 2020 21:22 UTC	TREVENA INC TRVN · Entity 85383	GrantStock Option (Right to Buy) · Derivative	64,103	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0001209191-20-029773 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,103 Underlying: Common Stock · 64,103 shares Expires 2030-05-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.